Patents by Inventor Kirk Willis Johnson

Kirk Willis Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CGRP Antibody Formulation
    Publication number: 20220112277
    Abstract: Pharmaceutical formulations for anti-CGRP antibodies, and methods of using the same, are provided which are useful as treatment for migraines, episodic headaches, chronic headaches, chronic cluster headaches, and episodic cluster headaches.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 14, 2022
    Inventors: Kirk Willis Johnson, William Brian Kielbasa, Tina Marie Myers-Oakes, Jason Michael Martinez, Aaron Leigh Schacht, Anant Sharma, Vlad Skljarevski
  • CHRONIC NIGHTLY DOSING OF LASMIDITAN FOR MIGRAINE PREVENTION
    Publication number: 20210338655
    Abstract: The present invention relates to chronic nightly use of lasmiditan for the prevention of migraine, particularly therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment or prevention regimens.
    Type: Application
    Filed: September 3, 2019
    Publication date: November 4, 2021
    Inventors: Robert Russell Conley, Gudarz Davar, Kirk Willis Johnson
  • Combination Therapy of Lasmiditan and a CGRP Antagonist for Use in the Treatment of Migraine
    Publication number: 20200268735
    Abstract: The present invention relates to combinations of lasmiditan and a calcitonin gene-related peptide (CGRP) antagonist, for example the combination of lasmiditan and galcanezumab, and to methods of using the combinations for treatment of migraine, particularly migraine inadequately controlled by lasmiditan or a CGRP antagonist therapy alone, and more particularly, to treat therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment regimens.
    Type: Application
    Filed: August 30, 2018
    Publication date: August 27, 2020
    Inventors: Sheena Aurora, Kirk Willis Johnson, John Henry Krege
  • Potentiators of glutamate receptors
    Patent number: 6800651
    Abstract: The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.
    Type: Grant
    Filed: November 20, 2002
    Date of Patent: October 5, 2004
    Assignee: Eli Lilly and Company
    Inventors: Darrell Stephen Coleman, Gunnar Erik Jagdmann, Kirk Willis Johnson, Michael Parvin Johnson, Thomas Hallett Large, James Allen Monn, Darryle Darwin Schoepp, Thomas Charles Britton, Steven Scott Henry, Joseph Patrick Tizzano
  • Potentiators of glutamate receptors
    Publication number: 20040006114
    Abstract: The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.
    Type: Application
    Filed: November 20, 2002
    Publication date: January 8, 2004
    Inventors: Darrell Stephen Coleman, Gunnar Erik Jagdmann, Kirk Willis Johnson, Michael Parvin Johnson, Thomas Hallett Large, James Allen Monn, Darryle Darwin Schoepp, David Anthony Barda, Thomas Charles Britton, Bruce Anthony Dressman, Steven Scott Henry, William Joseph Hornback, Joseph Patrick Tizzano, Michael William Fichtner
  • Selective iGluR5 receptor antagonists for the treatment of migraine
    Patent number: 6566370
    Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 receptor antagonists.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: May 20, 2003
    Assignee: Eli Lilly and Company
    Inventors: David Bleakman, Sandra Ann Filla, Kirk Willis Johnson, Paul Leslie Ornstein
  • Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F agonists
    Patent number: 6380201
    Abstract: This invention provides methods for the treatment or amelioration of the symptoms of the common cold or allergic rhinitis which comprises administering to a mammal in need thereof a serotonin 5-HT1F agonist.
    Type: Grant
    Filed: March 4, 1999
    Date of Patent: April 30, 2002
    Assignee: Eli Lilly and Company
    Inventors: Kirk Willis Johnson, Lee Alan Phebus
  • Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT.sub.1F
    Patent number: 5962473
    Abstract: This invention provides methods for the treatment or amelioration of the symptoms of the common cold or allergic rhinitis which comprises administering to a mammal in need thereof a serotonin 5-HT.sub.1F agonist.
    Type: Grant
    Filed: August 5, 1997
    Date of Patent: October 5, 1999
    Assignee: Eli Lilly and Company
    Inventors: Kirk Willis Johnson, Lee Alan Phebus
  • Methods of treating or ameliorating the symptoms of venomous bites and stings
    Patent number: 5886003
    Abstract: This invention provides a method for the treatment or amelioration of the symptoms of venomous bites or stings which comprises administering to a mammal in need thereof one or more 5-HT.sub.2 antagonists.
    Type: Grant
    Filed: March 7, 1997
    Date of Patent: March 23, 1999
    Assignee: Eli Lilly and Company
    Inventors: Marlene Lois Cohen, Kirk Willis Johnson
  • Method of treating or ameliorating the symptoms of common cold or allergic rhinitis
    Patent number: 5869497
    Abstract: This invention provides methods for the treatment or amelioration of the symptoms of the common cold or allergic rhinitis which comprises administering to a mammal in need thereof a 5-HT.sub.2 antagonist.
    Type: Grant
    Filed: March 7, 1997
    Date of Patent: February 9, 1999
    Assignee: Eli Lilly and Company
    Inventors: Kirk Willis Johnson, David Lloyd Garver Nelson, Lee Alan Phebus